Tuo Deng

Prof. Tuo Deng

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2021 in Frontiers in Medicine
Verified
Journal Article
Open access
BLBing Liu
Bing Liu
YYYing Yu
Ying Yu
WLWen Liu
Wen Liu
TDTuo Deng
Tuo Deng
DXDaoman Xiang
Daoman Xiang
Objective: We conducted a meta-analysis to explore all the potential risk factors for non-arteritic anterior ischemic optic neuropathy (NAION) based on the published literature.Methods: A comprehensive literature search through the online databases was performed to obtain studies concerning the risk factors of NAION up to June 2020. Pooled unadjusted odds ratios (ORs) or rate ratios (RRs) were calculated to evaluate the weight of risk factors. This study was registered in PROSPERO under the number CRD42018084960.Results: Our meta-analysis included 49 original studies comprising of more than 10 million patients. The following risk factors were proved to be significantly associated with NAION: male gender (OR = 1.67, 95% CI: 1.50–1.85, P < 0.00001), hypertension (RR = 1.28, 95% CI: 1.20–1.37, P < 0.00001), hyperlipidemia (RR = 1.43, 95% CI: 1.26–1.62, P < 0.00001), diabetes mellitus (DM) (RR = 1.53, 95% CI: 1.36–1.73, P < 0.00001), coronary heart disease (CHD) (RR = 1.68, 95% CI: 1.24–2.27, P = 0.0008), sleep apnea (RR = 3.28, 95% CI: 2.08–5.17, P < 0.00001), factor V Leiden heterozygous (RR = 2.21, 95% CI: 1.19–4.09, P = 0.01), and medication history of cardiovascular drugs.Conclusion: We concluded that the above risk factors were significantly related to NAION. Better understanding of these risk factors in NAION can help the direct therapeutic approaches.

12 December 2017 in BJU International
Verified
Journal Article
Closed access
PDF file
TDTuo Deng
Tuo Deng
BLBing Liu
Bing Liu
XDXiaolu Duan
Xiaolu Duan
CCChao Cai
Chao Cai
ZZZhijian Zhao
Zhijian Zhao
GZGuohua Zeng
Guohua Zeng

12 August 2019 in Clinical and Experimental Medicine
Verified
Journal Article
Closed access
YWYaoan Wen
Yaoan Wen
YCYeda Chen
Yeda Chen
XDxiaolu duan
xiaolu duan
WZWei Zhu
Wei Zhu
CCChao Cai
Chao Cai
GZGuohua Zeng
Guohua Zeng

5 June 2018 in Sexual Medicine
Verified
Journal Article
Open access
PDF file
BLBing Liu
Bing Liu
LZLinxin Zhu
Linxin Zhu
JZJingxiang Zhong
Jingxiang Zhong
GZGuohua Zeng
Guohua Zeng
TDTuo Deng
Tuo Deng
Phosphodiesterase type 5 inhibitors (PDE5-Is) are first-line drugs for erectile dysfunction. Non-arteritic anterior ischemic optic neuropathy (NAION) has been linked with PDE5-I use. However, no meta-analysis or conclusive review has explored the association between NAION and PDE5-I use. To investigate the association between PDE5-I use and risk of NAION. A comprehensive literature search was conducted using online databases in October 2017 to obtain studies researching the association between PDE5-I application and occurrence of NAION. Summarized unadjusted risk ratios (RRs) with 95% CIs were calculated for the strength of this association. This study was conducted in accordance to Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines and registered in PROSPERO under number CRD42017080865. The strength of association between PDE5-I use and risk of NAION was assessed through pooled unadjusted RRs and 95% CIs. 5 original articles with 6 clinical observations were included in the meta-analysis. No significant higher risk of NAION was observed after the use of PDE5-Is within a 1-month period (RR = 1.16, 95% CI = 0.98-1.39, P = .09). Subgroup analyses indicated 2 PDE5-Is were significantly related to NAION (tadalafil: RR = 2.14, 95% CI = 1.20–3.84, P = .01; sildenafil: RR = 2.25, 95% CI = 1.29–3.94, P = .004). Although we found no association between NAION and PDE5-I use, our results should be interpreted cautiously because we included only observational studies and could not control for potential confounders. Because NAION is a rare ocular disease and difficult to diagnose, this association should be confirmed in prospective comparative studies with larger samples and more rigorous designs. Liu B, Zhu L, Zhong J, et al. The Association Between Phosphodiesterase Type 5 Inhibitor Use and Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis. Sex Med 2018;6:185−192.

20 April 2018 in Cancer Science
Verified
Journal Article
Open access
PDF file
Zhenzhen KongZhenzhen Kong
Zhenzhen Kong
TDTuo Deng
Tuo Deng
MZMengping Zhang
Mengping Zhang
ZZZhijian Zhao
Zhijian Zhao
YLYang Liu
Yang Liu
XDxiaolu duan
xiaolu duan
Recently, β‐arrestin1 has been indicated as a prostate cancer promoter through promoting cell proliferation and epithelial to mesenchymal transition, but its underlying mechanism remains unclear. Here, our data revealed that β‐arrestin1 could promote cell growth through inhibiting the transcriptional activity and expression of FOXO3a in prostate cancer cells in vitro and in vivo. We found that β‐arrestin1 could promote the cell and tumor growth of prostate cancer, and β‐arrestin1 expression represented a negative correlation with FOXO3a expression but not FOXO1 expression in prostate cancer cell lines and tissues. In addition, forced expression of β‐arrestin1 induced a significant decrease of FOXO3a expression but had no clear effect on FOXO1 expression. Mechanistically, β‐arrestin1 could interact with FOXO3a and MDM2, respectively, and promote the interaction between FOXO3a and MDM2, whereas it had no obvious interaction with FOXO1. Furthermore, β‐arrestin1 could inhibit the transcriptional activity of FOXO3a via Akt and ERK1/2 pathways. Together, our results revealed a novel mechanism for β‐arrestin1 in the regulation of the prostate cancer procession through inhibiting FOXO3a.

20 November 2024 in BMC Women's Health
Verified
Journal Article
Open access
PDF file
LLLeqi Liang
Leqi Liang
SAShan Ao
Shan Ao
SWSu Wang
Su Wang
ZCZugen Chen
Zugen Chen
LPLei Peng
Lei Peng
TDTuo Deng
Tuo Deng
Le Fort colpocleisis is an obliterative surgery for the treatment of pelvic organ prolapse (POP). In this study, we aimed to investigate the efficacy and safety of Le Fort colpocleisis in the treatment of patients with stage III-IV POP. The study was designed as a retrospective analysis of a single-center case series. Patients with stage III-IV POP treated with Le Fort colpocleisis were included. Perioperative indicators, subjective and objective outcomes and complications were assessed. The POP-Quantification (POP-Q) system was used for objective outcome evaluation. Pelvic Floor Distress Questionnaire (PFDI-20) and Pelvic Floor Impact Questionnaire (PFIQ-7) were used for subjective outcome evaluation. A total of 54 patients with complete pre- and postoperative data completed follow-up and were included in our study. The mean ± standard deviation of operative time, intraoperative blood loss, recovery activity time, postoperative hospitalization time and total hospitalization time were 146.85 ± 37.01 min, 92.04 ± 68.31 ml, 2.81 ± 0.85 days, 6.5 ± 2.11 days and 13.52 ± 4.78 days, respectively. Within the median follow-up period of 38.5 months, the objective cure rate of Le Fort colpocleisis reached 98.15% (53/54), and the subjective cure rate reached 92.59% (50/54). No serious complications were reported during the perioperative period and follow-up period. Le Fort colpocleisis is an effective and safe procedure for the treatment of severe POP. Because of its lower operative risk, better subjective and objective outcomes, lower rates of prolapse recurrence and perioperative complications, Le Fort colpocleisis should be considered as the recommended procedure for elderly patients with severe POP (stage III-IV).